01427nas a2200229   4500008004100000022001400041245005200055210005100107260001600158300001100174490000700185520080300192653002000995653001901015653002301034653001701057653001301074653002101087653002101108100002001129856004801149       2014                        eng d  a1878-583200aGenomics and transcriptomics in drug discovery.0 aGenomics and transcriptomics in drug discovery  c2013 Jun 14  a126-320 v193 aThe popularization of genomic high-throughput technologies is causing a revolution in biomedical research and, particularly, is transforming the field of drug discovery. Systems biology offers a framework to understand the extensive human genetic heterogeneity revealed by genomic sequencing in the context of the network of functional, regulatory and physical protein-drug interactions. Thus, approaches to find biomarkers and therapeutic targets will have to take into account the complex system nature of the relationships of the proteins with the disease. Pharmaceutical companies will have to reorient their drug discovery strategies considering the human genetic heterogeneity. Consequently, modeling and computational data analysis will have an increasingly important role in drug discovery.10aadverse effects10aDrug discovery10adrug repositioning10ametagenomics10amodeling10anetwork analysis10apathway analysis1 aDopazo, Joaquin  uhttp://www.ncbi.nlm.nih.gov/pubmed/23773860